Last updated: July 1, 2025
Sponsor: Krystal Biotech, Inc.
Overall Status: Active - Recruiting
Phase
N/A
Condition
Epidermolysis Bullosa
Treatment
N/AClinical Study ID
NCT06563414
NHS
Ages > 6 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
The subject or their respective legal guardian must have read, understood, and signed an Institutional Review Board (IRB) approved Informed Consent/Assent Form and must be able to and willing to follow study procedures and instructions.
Age 6 months or older at time of Informed Consent/Assent.
Prior genetic diagnosis of DEB due to mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.
Study Design
Total Participants: 40
Study Start date:
August 02, 2024
Estimated Completion Date:
December 31, 2025
Study Description
Connect with a study center
Krystal Biotech
Pittsburgh, Pennsylvania 15203
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.